Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Intelgenx Technologies Corp IGXT

IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

GREY:IGXT - Post Discussion

Intelgenx Technologies Corp > Ships CBD Filmstrips to Heritage Cannabis
View:
Post by Betteryear2 on Aug 31, 2021 8:47am

Ships CBD Filmstrips to Heritage Cannabis

SAINT LAURENT, Quebec, Aug. 31, 2021 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings Corp.’s (“Heritage Cannabis”) (CSE:CANN) Canadian market launch of its “CB4 Control” branded product.

The CBD Filmstrips were produced at IntelGenx’s manufacturing facility under Canadian GPP conditions and registered as a product for sale with Health Canada as a cannabis product governed by the Cannabis Act.

Dr. Horst G. Zerbe, CEO of IntelGenx, commented, “Our partnership with Heritage Cannabis paved the way for our recent transition from a development-stage to a commercial-stage company. We are looking forward to continuing to work with Heritage Cannabis to make innovative and high-quality oral thin film products available to medical cannabis consumers.”

“We are proud that the CB4 Control filmstrips, based on IntelGenx’s Versafilm® platform, help comprise our new Opticann suite of branded products,” commented Umar Syed, President of the Medical Division at Heritage Cannabis. “We continue to believe the future of the oral cannabinoid market will be dominated by products based on innovative technologies such as VersaFilm® that are proven to deliver rapid and better absorption in a convenient dosage form.”

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

 
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities